{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:47:34Z","timestamp":1790394454069,"version":"4.1.0"},"reference-count":163,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/ppo.0b013e3182346320","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T18:53:11Z","timestamp":1317754391000},"page":"379-396","source":"Crossref","is-referenced-by-count":13,"title":["Multiple Vaccinations"],"prefix":"10.1097","volume":"17","author":[{"given":"Sarah E.","family":"Church","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn M.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Twitty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Bahjat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Ming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Urba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210203","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens.","volume":"357","author":"Amanna","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-17-20210203","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4161\/hv.4.4.5751","article-title":"Protective immunity following vaccination: how is it defined?","volume":"4","author":"Amanna","year":"2008","journal-title":"Hum Vaccine"},{"key":"R3-17-20210203","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.4049\/jimmunol.166.12.7370","article-title":"Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.","volume":"166","author":"Winter","year":"2001","journal-title":"J Immunol"},{"key":"R4-17-20210203","first-page":"2458","article-title":"Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene.","volume":"30","author":"Basombrio","year":"1970","journal-title":"Cancer Res"},{"key":"R5-17-20210203","first-page":"835","article-title":"Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.","volume":"13","author":"Foley","year":"1953","journal-title":"Cancer Res"},{"key":"R6-17-20210203","first-page":"1561","article-title":"Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.","volume":"20","author":"Klein","year":"1960","journal-title":"Cancer Res"},{"key":"R7-17-20210203","first-page":"1657","article-title":"Adoptive immunotherapy of newly induced murine sarcomas.","volume":"45","author":"Shu","year":"1985","journal-title":"Cancer Res"},{"key":"R8-17-20210203","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1158\/1078-0432.CCR-09-1113","article-title":"Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.","volume":"15","author":"LaCelle","year":"2009","journal-title":"Clin Can Res"},{"key":"R10-17-20210203","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/1078-0432.CCR-09-2377","article-title":"Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development.","volume":"15","author":"Eggermont","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"R11-17-20210203","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/jco.2008.26.15_suppl.9004","article-title":"EORTC18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4 N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results.","volume":"26","author":"Eggermont","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"R12-17-20210203","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/jco.2010.28.15_suppl.8505","article-title":"Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH\/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961.","volume":"28","author":"Eggermont","year":"2010","journal-title":"J Clin Oncol"},{"key":"R13-17-20210203","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.ejca.2009.05.004","article-title":"Therapeutic vaccines in solid tumours: can they be harmful?","volume":"45","author":"Eggermont","year":"2009","journal-title":"Eur J Cancer"},{"key":"R14-17-20210203","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10124","article-title":"A 2020 vision for vaccines against HIV, tuberculosis and malaria.","volume":"473","author":"Rappuoli","year":"2011","journal-title":"Nature"},{"key":"R16-17-20210203","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine.","volume":"346","author":"Frey","year":"2002","journal-title":"N Engl J Med"},{"key":"R17-17-20210203","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2010.09.011","article-title":"Induction of immunity to human immunodeficiency virus type-1 by vaccination.","volume":"33","author":"McElrath","year":"2010","journal-title":"Immunity"},{"key":"R18-17-20210203","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"R19-17-20210203","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AM.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine.","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol"},{"key":"R20-17-20210203","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1016\/j.vaccine.2009.08.007","article-title":"Hepatitis B immunity in adolescents and necessity for boost vaccination: 23 years after nationwide hepatitis B virus vaccination program in Taiwan.","volume":"27","author":"Lu","year":"2009","journal-title":"Vaccine"},{"key":"R21-17-20210203","doi-asserted-by":"crossref","first-page":"12754","DOI":"10.1128\/JVI.01763-10","article-title":"Antiviral immunity following smallpox virus infection: a case-control study. J.","volume":"84","author":"Hammarlund","year":"2010","journal-title":"Virol"},{"key":"R22-17-20210203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"R23-17-20210203","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1084\/jem.20062363","article-title":"Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.","volume":"204","author":"Precopio","year":"2007","journal-title":"J Exp Med"},{"key":"R24-17-20210203","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"R25-17-20210203","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines.","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"key":"R26-17-20210203","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.4049\/jimmunol.163.11.6292","article-title":"Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.","volume":"163","author":"Lee","year":"1999","journal-title":"J Immunol"},{"key":"R27-17-20210203","first-page":"4749","article-title":"Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.","volume":"56","author":"Salgaller","year":"1996","journal-title":"Cancer Res"},{"key":"R28-17-20210203","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jnci\/92.16.1336","article-title":"Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.","volume":"92","author":"Kammula","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R29-17-20210203","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2003.09.020","article-title":"Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.","volume":"21","author":"Smith","year":"2003","journal-title":"J Clin Oncol"},{"key":"R30-17-20210203","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/01.cji.0000190399.98802.10","article-title":"Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.","volume":"29","author":"Rosenberg","year":"2006","journal-title":"J Immunother"},{"key":"R31-17-20210203","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.4049\/jimmunol.175.9.6169","article-title":"Tumor progression can occur despite the induction of very high levels of self\/tumor antigen-specific CD8+ T cells in patients with melanoma.","volume":"175","author":"Rosenberg","year":"2005","journal-title":"J Immunol"},{"key":"R32-17-20210203","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00002371-200307000-00007","article-title":"Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.","volume":"26","author":"Phan","year":"2003","journal-title":"J Immunother"},{"key":"R33-17-20210203","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2010.33.8053","article-title":"Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.","volume":"29","author":"Slingluff","year":"2011","journal-title":"J Clin Oncol"},{"key":"R34-17-20210203","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1200\/JCO.2007.13.3165","article-title":"Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-Positive advanced melanoma.","volume":"26","author":"Sosman","year":"2008","journal-title":"J Clin Oncol"},{"key":"R35-17-20210203","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1078-0432.CCR-08-1231","article-title":"Immunogenicity and antitumor effects of vaccination with peptide vaccine +\/ granulocyte-monocyte colony-stimulating factor and\/or IFN- 2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group phase II trial E1696.","volume":"15","author":"Kirkwood","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R36-17-20210203","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2001.19.18.3836","article-title":"Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.","volume":"19","author":"Lee","year":"2001","journal-title":"J Clin Oncol"},{"key":"R37-17-20210203","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/1078-0432.CCR-10-3272","article-title":"Intra-lymph node prime-boost vaccination against melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial.","volume":"17","author":"Ribas","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R38-17-20210203","first-page":"1289","article-title":"Generation of immunity to the HER-2\/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.","volume":"5","author":"Disis","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R39-17-20210203","first-page":"73","article-title":"Expansion of HER2\/neu-specific T cells ex vivo following immunization with a HER2\/neu peptide-based vaccine.","volume":"2","author":"Knutson","year":"2001","journal-title":"Clin Br Can"},{"key":"R40-17-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-07-1881","article-title":"Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.","volume":"14","author":"Kenter","year":"2008","journal-title":"Clin Can Res"},{"key":"R41-17-20210203","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4049\/jimmunol.181.1.776","article-title":"Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.","volume":"181","author":"Adams","year":"2008","journal-title":"J Immunol"},{"key":"R42-17-20210203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/CJI.0b013e31819302f6","article-title":"Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2\/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.","volume":"32","author":"Bioley","year":"2009","journal-title":"J Immunother"},{"key":"R43-17-20210203","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1073\/pnas.0703395104","article-title":"Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody\/TH1 responses and CD8 T cells through cross-priming.","volume":"104","author":"Valmori","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R44-17-20210203","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2004.09.005","article-title":"Effect of dose on immune response in patients vaccinated with an her-2\/neu intracellular domain protein-based vaccine.","volume":"22","author":"Disis","year":"2004","journal-title":"J Clin Oncol"},{"key":"R45-17-20210203","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1073\/pnas.0707140104","article-title":"Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.","volume":"105","author":"Atanackovic","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R46-17-20210203","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.4049\/jimmunol.172.5.3289","article-title":"Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.","volume":"172","author":"Atanackovic","year":"2004","journal-title":"J Immunol"},{"key":"R47-17-20210203","first-page":"2973","article-title":"Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.","volume":"9","author":"Rosenberg","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R48-17-20210203","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00262-009-0782-8","article-title":"Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.","volume":"59","author":"Gulley","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"R49-17-20210203","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/0008-5472.CAN-10-2693","article-title":"Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.","volume":"71","author":"Corbiere","year":"2011","journal-title":"Cancer Res"},{"key":"R50-17-20210203","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2005.08.375","article-title":"Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.","volume":"23","author":"van Baren","year":"2005","journal-title":"J Clin Oncol"},{"key":"R51-17-20210203","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1073\/pnas.95.22.13141","article-title":"Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.","volume":"95","author":"Soiffer","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R52-17-20210203","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1200\/JCO.2003.07.005","article-title":"Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.","volume":"21","author":"Soiffer","year":"2003","journal-title":"J Clin Oncol"},{"key":"R53-17-20210203","first-page":"S173","article-title":"Allogeneic breast cancer cell vaccines.","volume":"3","author":"Dols","year":"2008","journal-title":"Clin Br Can"},{"key":"R54-17-20210203","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1089\/104303403322124828","article-title":"Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.","volume":"14","author":"Dols","year":"2003","journal-title":"Hum Gene Ther"},{"key":"R55-17-20210203","first-page":"1005","article-title":"Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp.","volume":"179","author":"Bakker","year":"1994","journal-title":"Med"},{"key":"R56-17-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00002371-200001000-00004","article-title":"Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.","volume":"23","author":"Kawakami","year":"2000","journal-title":"J Immunother"},{"key":"R57-17-20210203","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00002371-200205000-00008","article-title":"Frequency of MART-1\/melanA and gp100\/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.","volume":"25","author":"Seiter","year":"2002","journal-title":"J Immunother"},{"key":"R58-17-20210203","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nm0398-321","article-title":"Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.","volume":"4","author":"Rosenberg","year":"1998","journal-title":"Nat Med"},{"key":"R59-17-20210203","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R60-17-20210203","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.4049\/jimmunol.165.8.4246","article-title":"Divergent roles for CD4+ T cells in the priming and effector\/memory phases of adoptive immunotherapy.","volume":"165","author":"Hu","year":"2000","journal-title":"J Immunol"},{"key":"R61-17-20210203","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","article-title":"Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.","volume":"90","author":"Dranoff","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R62-17-20210203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jim.2005.09.011","article-title":"Maximizing the retention of antigen specific lymphocyte function after cryopreservation.","volume":"308","author":"Disis","year":"2006","journal-title":"J Immunol Meth"},{"key":"R63-17-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clim.2007.08.006","article-title":"Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2\/neu overexpressing cancers.","volume":"125","author":"Salazar","year":"2007","journal-title":"Clin Immunol"},{"key":"R64-17-20210203","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1158\/1078-0432.CCR-09-1544","article-title":"Effect of granulocyte\/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.","volume":"15","author":"Slingluff","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R65-17-20210203","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djh028","article-title":"Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.","volume":"96","author":"Nemunaitis","year":"2004","journal-title":"J Nat Cancer Inst"},{"key":"R66-17-20210203","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.cgt.7700922","article-title":"Phase 1\/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.","volume":"13","author":"Nemunaitis","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"R67-17-20210203","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cncr.23669","article-title":"Phase 1\/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.","volume":"113","author":"Higano","year":"2008","journal-title":"Cancer"},{"key":"R68-17-20210203","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","article-title":"Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R69-17-20210203","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1158\/1078-0432.CCR-09-1540","article-title":"Effect of granulocyte\/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine.","volume":"15","author":"Faries","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R70-17-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00002371-200303000-00009","article-title":"Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells.","volume":"26","author":"Dols","year":"2003","journal-title":"J Immunother"},{"key":"R71-17-20210203","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1016\/j.vaccine.2007.10.037","article-title":"Chitosan solution enhances the immunoadjuvant properties of GM-CSF.","volume":"25","author":"Zaharoff","year":"2007","journal-title":"Vaccine"},{"key":"R72-17-20210203","first-page":"5841","article-title":"Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.","volume":"53","author":"Golumbek","year":"1993","journal-title":"Cancer Res"},{"key":"R73-17-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1479-5876-5-43","article-title":"Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.","volume":"5","author":"Ruttinger","year":"2007","journal-title":"J Transl Med"},{"key":"R74-17-20210203","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1158\/0008-5472.CAN-04-0757","article-title":"High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.","volume":"64","author":"Serafini","year":"2004","journal-title":"Cancer Res"},{"key":"R75-17-20210203","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1172\/JCI30966","article-title":"MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.","volume":"117","author":"Jinushi","year":"2007","journal-title":"J Clin Invest"},{"key":"R76-17-20210203","doi-asserted-by":"crossref","first-page":"8889","DOI":"10.1158\/0008-5472.CAN-08-2147","article-title":"Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment.","volume":"68","author":"Jinushi","year":"2008","journal-title":"Cancer Res"},{"key":"R77-17-20210203","doi-asserted-by":"crossref","first-page":"8ra19","DOI":"10.1126\/scitranslmed.3000359","article-title":"In situ regulation of DC subsets and t cells mediates tumor regression in mice.","volume":"1","author":"Ali","year":"2009","journal-title":"Sci Transl Med"},{"issue":"suppl","key":"R78-17-20210203","first-page":"9011","article-title":"Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC melanoma group (16032-18031).","volume":"27","author":"Kruit","year":"2008","journal-title":"J Clin Oncol"},{"key":"R79-17-20210203","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1200\/JCO.2008.20.6789","article-title":"Concurrent trastuzumab and HER2\/neu-specific vaccination in patients with metastatic breast cancer.","volume":"27","author":"Disis","year":"2009","journal-title":"J Clin Oncol"},{"key":"R80-17-20210203","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-10-0948","article-title":"A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.","volume":"16","author":"Nesslinger","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R81-17-20210203","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1023\/B:JOCI.0000040928.67495.52","article-title":"Humoral epitope-spreading following immunization with a HER-2\/neu peptide based vaccine in cancer patients.","volume":"24","author":"Disis","year":"2004","journal-title":"J Clin Immunol"},{"key":"R82-17-20210203","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0198-8859(02)00401-9","article-title":"Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2\/neu after active immunization in an ovarian cancer patient.","volume":"63","author":"Knutson","year":"2002","journal-title":"Hum Immunol"},{"key":"R83-17-20210203","first-page":"998","article-title":"Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.","volume":"9","author":"Butterfield","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R84-17-20210203","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood.V96.9.3102","article-title":"Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.","volume":"96","author":"Brossart","year":"2000","journal-title":"Blood"},{"key":"R85-17-20210203","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.1999.17.3.1047","article-title":"Cancer vaccines.","volume":"17","author":"Greten","year":"1999","journal-title":"J Clin Oncol"},{"key":"R86-17-20210203","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/eji.201040310","article-title":"Modulating numbers and phenotype of CD8+ T cells in secondary immune responses.","volume":"40","author":"Wirth","year":"2010","journal-title":"Eur J Immunol"},{"key":"R87-17-20210203","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1128\/JVI.75.13.5965-5976.2001","article-title":"Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses.","volume":"75","author":"McNally","year":"2001","journal-title":"J Virol"},{"key":"R88-17-20210203","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"key":"R89-17-20210203","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"R90-17-20210203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CJI.0b013e3181611420","article-title":"Phase 1 trial of intranodal injection of a melan-A\/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.","volume":"31","author":"Weber","year":"2008","journal-title":"J Immunother"},{"key":"R91-17-20210203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-065X.2007.00573.x","article-title":"The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.","volume":"220","author":"Apetoh","year":"2007","journal-title":"Immunol Rev"},{"key":"R92-17-20210203","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2545","article-title":"Immunogenic and tolerogenic cell death.","volume":"9","author":"Green","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"R93-17-20210203","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R94-17-20210203","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D immunoreceptor and its ligands.","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"R95-17-20210203","first-page":"1002","article-title":"Elevated soluble major histocompatibility complex class I chain-related protein A predicts nonresponsiveness to cytotoxic T lymphocyte antigen-4 blockade.","volume":"32","author":"Bahjat","year":"2009","journal-title":"J Immunother"},{"key":"R96-17-20210203","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1073\/pnas.0603503103","article-title":"Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.","volume":"103","author":"Jinushi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R97-17-20210203","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"R98-17-20210203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2001.19.1.145","article-title":"Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.","volume":"19","author":"Jaffee","year":"2001","journal-title":"J Clin Oncol"},{"key":"R99-17-20210203","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SLA.0b013e3181fd271c","article-title":"A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation.","volume":"253","author":"Lutz","year":"2011","journal-title":"Ann Surg"},{"key":"R100-17-20210203","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-07-0371","article-title":"Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.","volume":"14","author":"Laheru","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R101-17-20210203","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","article-title":"K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R102-17-20210203","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2009-02-205278","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).","volume":"114","author":"Borrello","year":"2009","journal-title":"Blood"},{"key":"R103-17-20210203","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1200\/JCO.2009.23.3494","article-title":"Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.","volume":"27","author":"Emens","year":"2009","journal-title":"J Clin Oncol"},{"key":"R104-17-20210203","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002371-199607000-00006","article-title":"Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.","volume":"19","author":"MacLean","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"R105-17-20210203","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1158\/1078-0432.CCR-04-2062","article-title":"Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.","volume":"11","author":"Gulley","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R106-17-20210203","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy.","volume":"6","author":"Zou","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"R107-17-20210203","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"R108-17-20210203","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-08-2632","article-title":"NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.","volume":"15","author":"Gnjatic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R110-17-20210203","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"R111-17-20210203","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature03337","article-title":"CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.","volume":"434","author":"Janssen","year":"2005","journal-title":"Nature"},{"key":"R112-17-20210203","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.1083317","article-title":"Defective CD8 T cell memory following acute infection without CD4 T cell help.","volume":"300","author":"Sun","year":"2003","journal-title":"Science"},{"key":"R113-17-20210203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1749-6632.2009.04939.x","article-title":"Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.","volume":"1174","author":"Rech","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"R114-17-20210203","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","article-title":"Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.","volume":"115","author":"Dannull","year":"2005","journal-title":"J Clin Invest"},{"key":"R115-17-20210203","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0897.2005.00330.x","article-title":"Regulatory T cells in ovarian cancer: biology and therapeutic potential.","volume":"54","author":"Barnett","year":"2005","journal-title":"Am J Reprod Immunol"},{"key":"R116-17-20210203","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0889-8588(03)00110-2","article-title":"Interleukin-2 receptor-directed therapies for cutaneous lymphomas.","volume":"17","author":"Foss","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"R117-17-20210203","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/1078-0432.CCR-10-1757","article-title":"Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I\/II study in metastatic melanoma patients.","volume":"16","author":"Jacobs","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R118-17-20210203","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1158\/1078-0432.CCR-10-2227","article-title":"Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.","volume":"17","author":"de Vries","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R119-17-20210203","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CJI.0b013e31815dc0e8","article-title":"Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.","volume":"31","author":"Powell","year":"2008","journal-title":"J Immunother"},{"key":"R120-17-20210203","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nm.2365","article-title":"A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.","volume":"17","author":"Wuest","year":"2011","journal-title":"Nat Med"},{"key":"R121-17-20210203","first-page":"963","article-title":"Evaluation of a novel human CD4+CD25DIMFOXP3- T-cell population in cancer patients undergoing interleukin-2 treatment abstract.","volume":"32","author":"Triplett","year":"2009","journal-title":"J Immunother"},{"key":"R122-17-20210203","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20020190","article-title":"Interleukin 2 signaling is required for CD4(+) regulatory T cell function.","volume":"196","author":"Furtado","year":"2002","journal-title":"J Exp Med"},{"key":"R123-17-20210203","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1073\/pnas.94.7.3168","article-title":"Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor.","volume":"94","author":"Sharfe","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R124-17-20210203","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"R125-17-20210203","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/0008-5472.CAN-06-2389","article-title":"A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.","volume":"67","author":"Suzuki","year":"2007","journal-title":"Cancer Res"},{"key":"R126-17-20210203","first-page":"2099","article-title":"An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.","volume":"29","author":"Rausch","year":"2009","journal-title":"Anticancer Res"},{"key":"R127-17-20210203","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice.","volume":"181","author":"Youn","year":"2008","journal-title":"J Immunol"},{"key":"R128-17-20210203","doi-asserted-by":"crossref","first-page":"8270","DOI":"10.1158\/1078-0432.CCR-08-0165","article-title":"Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.","volume":"14","author":"Kusmartsev","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R129-17-20210203","first-page":"4441","article-title":"All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.","volume":"63","author":"Kusmartsev","year":"2003","journal-title":"Cancer Res"},{"key":"R130-17-20210203","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.","volume":"203","author":"Serafini","year":"2006","journal-title":"J Exp Med"},{"key":"R131-17-20210203","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-10-4316","article-title":"Tumor-evoked regulatory b cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells.","volume":"71","author":"Olkhanud","year":"2011","journal-title":"Cancer Res"},{"key":"R132-17-20210203","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/intimm\/10.8.1057","article-title":"B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state.","volume":"10","author":"Wijesuriya","year":"1998","journal-title":"Int Immunol"},{"key":"R133-17-20210203","doi-asserted-by":"crossref","first-page":"20878","DOI":"10.1073\/pnas.0709205105","article-title":"Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice.","volume":"104","author":"Bouaziz","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R134-17-20210203","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00262-011-0972-z","article-title":"The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model.","volume":"60","author":"Tadmor","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"R135-17-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1084\/jem.179.1.249","article-title":"Tolerogenicity of resting and activated B cells.","volume":"179","author":"Gilbert","year":"1994","journal-title":"J Exp Med"},{"key":"R136-17-20210203","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N Engl J Med"},{"key":"R137-17-20210203","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.immuni.2008.11.002","article-title":"Homeostasis of Naive and Memory T Cells.","volume":"29","author":"Surh","year":"2008","journal-title":"Immunity"},{"key":"R138-17-20210203","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cell.2011.01.011","article-title":"IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology.","volume":"144","author":"Pellegrini","year":"2011","journal-title":"Cell"},{"key":"R139-17-20210203","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/eji.200839210","article-title":"CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.","volume":"40","author":"Wang","year":"2010","journal-title":"Eur J Immunol"},{"key":"R140-17-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.cji.0000210386.55951.c2","article-title":"IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.","volume":"29","author":"Rosenberg","year":"2006","journal-title":"J Immunother"},{"key":"R141-17-20210203","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1078-0432.CCR-09-1303","article-title":"Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.","volume":"16","author":"Sportes","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R142-17-20210203","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1182\/blood-2010-03-275438","article-title":"Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates.","volume":"116","author":"Lugli","year":"2010","journal-title":"Blood"},{"key":"R143-17-20210203","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"R144-17-20210203","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"R146-17-20210203","first-page":"335","article-title":"Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.","volume":"12","author":"Cooke","year":"2006","journal-title":"Nature"},{"key":"R148-17-20210203","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.","volume":"111","author":"Hinrichs","year":"2008","journal-title":"Blood"},{"key":"R149-17-20210203","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2007-05-089375","article-title":"IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.","volume":"111","author":"Li","year":"2007","journal-title":"Blood"},{"key":"R150-17-20210203","doi-asserted-by":"crossref","first-page":"732","DOI":"10.4049\/jimmunol.178.2.732","article-title":"IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes.","volume":"178","author":"Peluso","year":"2007","journal-title":"J Immunol"},{"key":"R151-17-20210203","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.4049\/jimmunol.175.4.2261","article-title":"IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response.","volume":"175","author":"Li","year":"2005","journal-title":"J Immunol"},{"key":"R152-17-20210203","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1158\/1078-0432.CCR-08-2663","article-title":"Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.","volume":"15","author":"Davis","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R153-17-20210203","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1126\/science.7513904","article-title":"Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.","volume":"264","author":"Huang","year":"1994","journal-title":"Science"},{"key":"R154-17-20210203","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4161\/auto.5.4.8366","article-title":"Cross-presentation of tumor associated antigens through tumor-derived autophagosomes.","volume":"5","author":"Li","year":"2009","journal-title":"Autophagy"},{"key":"R155-17-20210203","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.it.2006.06.008","article-title":"The DRiP hypothesis decennial: support, controversy, refinement and extension.","volume":"27","author":"Yewdell","year":"2006","journal-title":"Trends Immunol"},{"key":"R156-17-20210203","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1158\/0008-5472.CAN-08-0161","article-title":"Efficient cross-presentation depends on autophagy in tumor cells.","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res"},{"key":"R158-17-20210203","doi-asserted-by":"crossref","first-page":"7125","DOI":"10.4049\/jimmunol.173.12.7125","article-title":"Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.","volume":"173","author":"Robbins","year":"2004","journal-title":"J Immunol"},{"key":"R159-17-20210203","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"R160-17-20210203","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1200\/JCO.2003.10.005","article-title":"Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.","volume":"21","author":"Slingluff","year":"2003","journal-title":"J Clin Oncol"},{"key":"R161-17-20210203","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1158\/1078-0432.CCR-10-2234","article-title":"Recommendations from the iSBTc-SITC\/FDA\/NCI Workshop on immunotherapy biomarkers.","volume":"17","author":"Butterfield","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R162-17-20210203","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"R163-17-20210203","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","article-title":"Clinical impact of different classes of infiltrating T cytotoxic and helper cells (TH1, TH2, Treg, TH17) in patients with colorectal cancer.","volume":"71","author":"Tosolini","year":"2011","journal-title":"Cancer Res"},{"key":"R164-17-20210203","doi-asserted-by":"crossref","first-page":"e6412","DOI":"10.1371\/journal.pone.0006412","article-title":"Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.","volume":"4","author":"Milne","year":"2009","journal-title":"PLoS ONE"},{"key":"R165-17-20210203","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res"},{"key":"R168-17-20210203","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","article-title":"Twelve immunotherapy drugs that could cure cancers.","volume":"222","author":"Cheever","year":"2008","journal-title":"Immunol Rev"},{"key":"R169-17-20210203","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R170-17-20210203","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1158\/1078-0432.CCR-08-1266","article-title":"Translational Research Working Group developmental pathway for immune response modifiers.","volume":"14","author":"Cheever","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R171-17-20210203","first-page":"abstract","article-title":"Exploiting the humoral immune response to identify tumor\/tumor-associated antigens recognized after combination immunotherapy in men with hormone-refractory prostate cancer.","volume":"975","author":"Puri","year":"2009","journal-title":"J Immunother"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00130404-201109000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:23:29Z","timestamp":1786047809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00130404-201109000-00017"}},"subtitle":["Friend or Foe"],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":163,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e3182346320","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}